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Using recombinant (r)HBsAg as a ligand, we previously found a 46-kDa human plasma protein capable of specific binding,
and identified this protein as apolipoprotein H (apo H). Apo H is able to bind to rHBsAg containing only the small S protein,
in both ligand blot and enzyme immunoassay systems (H. Mehdi, M. J. Kaplan, F. Y. Anlar., X. Yang, R. Bayer, K. Sutherland,
and M. E. Peeples, J. Virol. 68, 2415–2424, 1994). Apo H is a plasma glycoprotein, some of which is associated with
lipoproteins, particularly chylomicrons and high-density lipoproteins (HDL). During normal lipid trafficking in the bloodstream,
chylomicrons and HDL are targeted to the hepatocyte, the primary host cell for HBV, for degradation. In this report the
method of apo H presentation was examined. rHBsAg bound to apo H very poorly if the apo H was coated directly on a
microtiter well, or if it was presented in a soluble form. Binding was 100-fold more efficient when apo H was presented as
a complex with monoclonal antibody (MAb) P2D4. These results suggest that binding to this MAb alters apo H, making it
highly reactive with rHBsAg. Apo H binding to rHBsAg is not dependent on divalent cations and is optimal at pH 6.5–8.0.
Removal of lipids from rHBsAg resulted in denaturation, preventing analysis of binding activity. Removal of sialic acid or
complete removal of N-linked carbohydrates from apo H did not change its ability to bind rHBsAg, indicating that apo H
carbohydrates are not involved in rHBsAg binding. Likewise, chemical modification of the arginine residues of apo H had
no effect on binding. However, chemical modification of as few as three of the 29 lysine residues of apo H destroyed
binding, indicating that one or a few lysines in apo H are involved in rHBsAg binding. q 1996 Academic Press, Inc.
INTRODUCTION this protein as the plasma apolipoprotein H (apo H)
(Mehdi et al., 1994), also known as b2-glycoprotein I. Apo
To initiate infection, a virus must attach to a host cell H belongs to a family of proteins containing short (61
receptor via one of its surface (S) protein. Hepatitis B amino acid) consensus repeats (SCR) (Klickenstein et al.,
virus (HBV) has three related surface proteins, small S, 1987; Lozier et al., 1984). It is interesting that three other
middle S, and large S. All three of these proteins share virus receptors are members of the SCR family of pro-
the 226-amino-acid small S sequence at their C-termini, teins: complement receptor 2, the Epstein–Barr virus re-
but middle S has an amino terminal extension (pre-S2), ceptor (Fingeroth et al., 1984); membrane cofactor pro-
and large S has a further extension (pre-S1). It is not tein, the measles virus receptor (Dorig et al., 1993; Nani-
clear which of these three proteins serves as the HBV che et al., 1993); and decay accelerating factor, the
attachment protein (Marion, 1991), nor which hepatocyte echovirus, type 7 receptor (Bergelson et al., 1994).
protein acts as its receptor. We cDNA-cloned the apo H transcript, expressed it
We previously found that rHBsAg binds to a plasma
transiently in cell culture (Mehdi et al., 1991), and demon-
membrane-enriched fraction isolated from human liver
strated that recombinant apo H is able to bind rHBsAg
(Pontisso et al., 1989), particularly to a 46-kDa molecule
(Mehdi et al., 1994), confirming the identity of this binding
in that fraction (Mehdi et al., 1994). The association of
protein. Mature apo H is a 326-amino-acid protein (Lozier
this protein with the plasma membrane can be disrupted
et al., 1984) found on plasma lipoproteins as well as free
with a weak acid treatment suggesting that it is a periph-
in the plasma (Lee et al., 1983; Polz and Kostner, 1979).
eral or receptor-bound protein (M. J. Kaplan, and M. E.
We have suggested that HBV might bind to apo H on
Peeples, unpublished data). We subsequently identified
lipoprotein particles and be taken into hepatocytes as a
complex with these lipoproteins (Mehdi et al., 1994). This
hypothesis is attractive since the apo H found on lipopro-1 Present address: Department of Medicinal Chemistry and Pharma-
teins is primarily found on chylomicrons and HDL, bothcognosy, College of Pharmacy, University of Illinois at Chicago, Chi-
cago, Illinois 60612. of which are targeted to the hepatocyte during normal
2 Present address: Department of Infectious Diseases, Second Affili- lipid processing.
ated Hospital, Hunan Medical 6 University, Chang Sha, Hunan, People’s In this study we have further characterized the interac-Republic of China.
tion between rHBsAg and apo H. Using two microtiter3 To whom correspondence and reprint requests should be ad-
dressed. assays, one in which apo H is directly coated on the
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wells and the other in which apo H is captured by a MAb unbound apo H was washed away and incubated with
rHBsAg. Bound rHBsAg was detected with anti-HBs anti-against this protein, we have found evidence for two
forms of apo H: the microtiter well-bound form that reacts serum (DAKO), followed by rabbit anti-goat IgG–alkaline
phosphatase and substrate.poorly with rHBsAg (and soluble apo H which binds
rHBsAg equally poorly) and a MAb-bound form that is Ligand blotting. Purified apo H was solubilized in SDS
sample buffer under nonreducing conditions, unless oth-highly reactive with rHBsAg. We have determined the
pH optimum and cation requirement of rHBsAg particle erwise noted, and separated by SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) (Laemmli, 1970) on 12.5%interaction with apo H.
We have also examined some of the structural charac- polyacrylamide gels. Prestained molecular weight mark-
ers (Diversified Biotech) were used to calibrate proteinteristics of apo H to determine their importance in this
interaction. We previously demonstrated that treatment migration. Gels were electroblotted to nitrocellulose ac-
cording to the method supplied by the apparatus manu-of apo H with a reducing agent destroys its ability to bind
to rHBsAg (Mehdi et al., 1994), indicating that at least 1 facturer (Hoeffer Scientific Instruments). The nitrocellu-
lose blots were blocked with 5% BSA, fraction V (Sigmaof its 11 disulfide bonds (Bendixen et al., 1992; Kato and
Enjoyii, 1991) is required for this binding activity. Here Chemical Co.) in PBS, pH 7.4, incubated with 0.25 to 1.0
mg rHBsAg per lane diluted in 5% BSA in PBS at 227 forwe have chemically altered the apo H protein, removing
its sialic acid or all of its N-linked carbohydrate side 2 hr, washed six times with PBS, and followed by incuba-
tion with H166, a MAb specific for small S (a gift fromchains, without affecting binding, indicating that carbohy-
drates on apo H are not important in the binding activity. Dr. L. Mimms, Abbott Labortories) diluted in 5% BSA for
2 hr at 227. Bound antibody was detected with alkalineWe have also chemically modified the lysine residues of
apo H, which destroys its binding activity, indicating that phosphastase-labeled goat anti-mouse immunoglobulin
(Kirkegaard & Perry Laboratories, Inc.), as describedlysine residues are important for binding rHBsAg.
(Mehdi et al., 1994).
Glycosidase treatments. Apo H (0.1 mg) was treatedMATERIALS AND METHODS
with 0.1 units (U) of neuraminidase (Clostridium per-
fringens, Type V, Sigma Chemical Co.) in 30 ml of 20 mMrHBsAg and apo H. The rHBsAg used throughout this
study, S,L*, was a gift from Dr. T. Rutgers (SmithKline- sodium phosphate buffer (PB), pH 5.0, at 47 for 16 hr,
followed by 377 for 2 hr. Apo H was prepared for digestionBiologicals, Rixenart, Belgium). This rHBsAg, was pro-
duced in yeast by coexpression of a wild-type S gene, by N-glycosidase F (peptide-N-glycosidase F from Flavo-
bacterium meningosepticum) (Boehringer Mannheimand an L gene with deletions in the pre-S region (Cabe-
zon et al., 1990). We have previously demonstrated that Corp.) or O-glycosidase (endo-a-N-acetylgalactosamini-
dase from Diplococcus pneumoniae) (Boehringer Mann-the pre-S domain is not required for binding to apo H
(Mehdi et al., 1994). Apo H was isolated from the serum heim Corp.) by boiling 1.0 mg of purified apo H for 2 min
in 1% SDS, and diluting with 9 vol of 20 mM PB, pHof healthy individuals, as described in detail previously
(Mehdi et al., 1994). Serum-derived HBsAg particles, a 7.1, and 1% Nonidet P-40. O-Glycosidase (1.5 mU) or N-
glycosidase F (0.8 U) was added and digestions weregift from J. Gerin, were isolated by two ultracentrifugation
steps to pellet the virus and contained a high concentra- performed for 18 hr at 377.
Chemical modifications. Cyclohexanedione was usedtion of Dane particles, as determined by electron micros-
copy (Kaplan et al., 1973). to modify arginines. Three micrograms of purified apo H
was treated with 1,2-cyclohexanedione as described byEnzyme immunoassays. For the direct-coating assay,
vinyl 96-well assay plates (Costar, Cambridge, MA) were Mahley et al. (1977) in a total reaction volume of 75 ml.
Following a 2-hr incubation at 377, the sample was de-coated with increasing amounts of purified apo H in 50
ml PBS, covered, and incubated at 47C overnight, washed salted by 3 cycles of centrifugation in a Centricon 10
(Amicon), diluting after each cycle with water.three times with PBS, followed by blocking with 100 ml
1% bovine serum albumin (BSA) in PBS (the diluent used Lysines were acetoacetylated by treatment with diket-
ene (Sigma Chemical Co.) in 0.3 M sodium borate buffer,in all subsequent additions) at 377 for 1 hr. After three
washes with PBS, wells were incubated with biotinylated pH 8.5, for 10 min at 227 (Weisgraber et al., 1978). Purified
apo H was diluted in 0.3 M sodium borate buffer (pH 8.5)rHBsAg in 50 ml PBS with 1% BSA for 2 hr at 377. The
bound rHBsAg was detected by streptavidin–alkaline and diketene was added to a final concentration of 10
mM, incubated at 227 for 10 min, and desalted threephosphatase and substrate, para-nitrophenyl phosphate
(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, times. Acetoacylation of lysines was reversed by treat-
ment with hydroxylamine. Hydroxylamine (Sigma Chemi-MD). The color intensity was determined at 405 nm wave-
length using a Titertek Multiskan MC (ICN/Flow Labora- cal Co.), pH 6.95, was added to a concentration of 0.5 M
and incubated at 377 for 16 hr.tories). The capture assay was performed as described
(Mehdi et al., 1994). Briefly, wells were coated with MAb The number of acetoacylated lysines was determined
by an indirect procedure (Weisgraber et al., 1978): theP2D4, purified apo H (50 ml; 10 ng/ml) was added, and
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binds directly to the well in an orientation that does not
expose the rHBsAg binding site; or (2) apo H changes
its conformation upon binding to MAb P2D4 and be-
comes much more reactive with rHBsAg. If the first possi-
bility is true, soluble apo H should be able to compete
for rHBsAg binding to apo H on a microtiter well. If the
second possibility is true, soluble apo H should not be
able to compete for rHBsAg binding to apo H, but an apo
H/MAb complex should.
To test these possibilities, rHBsAg binding to apo H
on microtiter wells was examined in the presence of
increasing concentrations of soluble apo H, or of soluble
apo H plus MAb P2D4. (For this experiment, microtiter
wells directly coated with apo H were used because
MAb-coated wells were found to bind more rHBsAg as
FIG. 1. Comparison of the ability of apo H to bind rHBsAg depending
the concentration of competing apo H was increased,on the mode of apo H presentation. Increasing amounts of apo H were
probably due to the capture of additional apo H by thedirectly coated onto microtiter wells (l) or captured on microtiter wells
by MAb P2D4 (s). Wells were then incubated with biotinylated rHBsAg MAb.) As shown in Fig. 2, apo H was a more effective
and the relative amount of biotinylated rHBsAg bound was determined competitor in the presence of MAb P2D4 than in its ab-
by the addition of streptavidin– alkaline phosphatase followed by sub- sence. Large quantities of soluble apo H were required to
strate.
compete for rHBsAg binding: relative to the buffer control,
50% inhibition was reached at a concentration of 8 mg/
ml apo H. Apo H in the presence of MAb P2D4 inhibitedprotein was treated with dinitroflurobenzene to convert
50% of the rHBsAg particle binding at an approximatelyunreacted lysine residues into acid-stable dinitrophenyl
100-fold lower concentration. MAb P2D4 alone had noderivatives. Acid hydrolysis then converted the acetoacyl-
effect on this interaction. An additional control, an irrele-lysine residues to lysine, and these lysine residues were
vant MAb added to apo H, had no competative effect.quantified relative to the nitrophenyllysines. Amino acid
These results suggest that MAb P2D4 binding to apo Hanalyses were performed by K.-L. Ngai (Biotechnology
alters its conformation, making it much more reactiveFacility, Northwestern University, Chicago).
with rHBsAg.Carbamylation and reductive methylation of apo H
Analysis of serum-derived HBsAg particles for associ-were performed as previously described (Weisgraber et
ated apo H. To determine whether HBsAg isolated fromal., 1978).
human serum has associated apo H, we performed an
RESULTS
Dependence of rHBsAg binding on the method of apo
H presentation. We have developed two microtiter
assays to analyze rHBsAg binding to apo H. In the first
assay, apo H is directly coated on the microtiter well. In
the second assay, the microtiter well is first coated with
MAb P2D4, and apo H is captured by this antibody. In
both assays biotinylated rHBsAg is added, and bound
rHBsAg is detected by streptavidin–alkaline phospha-
tase.
rHBsAg bound to apo H presented in either manner
(Fig. 1), but there was a large difference in the amount of
apo H required for similar rHBsAg binding. Approximately
100-fold more apo H was required in the directly coated
plate compared to the MAb-capture plate. This difference FIG. 2. Competition for rHBsAg binding to apo H by soluble apo
is not due to the efficiency of apo H binding to the wells H. Microtiter wells were directly coated with purified apo H. Various
concentrations of purified apo H were incubated with PBS, or 4 mg/mlsince approximately 50% of the added apo H bound to
of MAb P2D4 or of an irrelevant MAb to the P protein of Newcastlethe microtiter wells in both cases (H. Mehdi and M. E.
disease virus, for 8 hr at 227. These mixtures were then added toPeeples, data not presented). Apo H directly coated on
biotinylated rHBsAg particles and incubated at 227 for 8 hr before
a microtiter well was, therefore, much less reactive with adding to the microtiter wells and incubating for 16 hr at 227. Bound,
rHBsAg than apo H presented on the MAb. The two most biotinylated rHBsAg was detected by streptavidin–alkaline phospha-
tase followed by substrate.likely explanations for this result would be: (1) apo H
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FIG. 3. Attempt to detect apo H on HBsAg isolated from human serum. Three preparations of HBsAg (I, II, III) isolated from different donors
(Kaplan et al., 1973) were reduced, displayed by SDS–PAGE, transferred to nitrocellulose, and probed with MAb H166 to small S (A) or with rabbit
anti-apo H (B). Two micrograms of total protein was loaded in the blot shown in A, and 10 mg in B. Twofold dilutions of purified apo H were also
analyzed in B as standards.
immunoblot of three preparations of HBsAg, enriched in activity might be responsible for its association with the
plasma lipoproteins, chylomicrons and HDL, since, un-Dane particles (Kaplan et al., 1973). The blots were
stained for HBsAg proteins (Fig. 3A) or for apo H (Fig. like the other apolipoproteins, apo H does not contain
significant stretches of hydrophobic amino acids (Stein-3B). Small S proteins, at approximately 24 and 27 kDa,
and large S proteins, at approximately 40 kDa, were de- kasserer et al., 1991). Neurath and Strick (1994) reported
that apo H directly presented on a microtiter well bindstected in all three HBsAg preparations. Five times more
material (approximately 10 mg) from these HBsAg prepa- weakly to HBsAg, removal of lipids from HBsAg destroys
this weak interaction, and relipidation restores it. Theyrations was examined for apo H. No apo H was detect-
able, indicating that these preparations contain less than suggested that apo H binds to the lipids in the HBsAg
particles, rather than to the viral proteins. The weak bind-15 ng of apo H, the lowest amount detected in standards
run in this assay. If one HBsAg particle contains 100 ing activity that they detected when apo H was presented
on the surface of a microtiter well is consistent with themolecules, there is less than 0.2 molecules of apo H per
serum-derived HBsAg particle. This finding is consistent weak binding that we found under similar conditions (Fig.
1), or when apo H was presented as a soluble competitorwith the results shown above, especially the competition
experiments (Fig. 2): soluble apo H does not associate (Fig. 2).
with HBsAg.
Effects of divalent cations and pH on binding. The ef-
fects of Ca2/ and Mg2/ on rHBsAg binding to apo H was
examined (Fig. 4). Apo H was presented on the MAb
P2D4 bound to microtiter plates. rHBsAg diluted in PBS
with no, or increasing concentrations of Ca2/ or Mg2/,
or with EDTA in the absence of Ca2/ and Mg2/, was then
added to the wells. rHBsAg was able to bind to apo H
regardless of the presence of Ca2/ or Mg2/, indicating
that these divalent cations are not necessary for binding.
Consistent with these findings, EDTA, which would che-
late any residual Ca2/ or Mg2/, had no effect on binding.
The effect of pH on rHBsAg binding to apo H was exam-
ined (Fig. 5). Apo H was presented on MAb P2D4 bound
to microtiter plates. rHBsAg added in various pH buffers,
FIG. 4. Effects of Ca2/, Mg2/, and EDTA on rHBsAg binding to apoeach within its effective buffering range, was able to bind
H. Apo H (10 ng/ml) was captured by MAb P2D4 coated on microtiterto apo H over a broad pH range, but the optimal binding
wells. Wells were incubated with 50 ml of rHBsAg (2 mg/ml) in Ca2/-
activity was found between pH 6.5 and 8.0. and Mg2/-free PBS supplemented with the indicated concentrations of
Removal of lipids from rHBsAg. Apo H binds to nega- Ca2/ (l), Mg2/ (m), or EDTA (/). Bound rHBsAg was detected with
goat anti-HBs antiserum.tively charged phospholipids (Wurm, 1984). This binding
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the N-glycan linkage of glycoproteins between aspara-
gine and the carbohydrate chain, reduces the apparent
molecular weight of apo H by approximately 15 kDa (lane
6), suggesting that all four potential N-linked carbohy-
drate sites are utilized, and that all N-linked carbohy-
drates are removed by N-glycosidase F.
O-Glycosidase cleaves the O-linked disaccharide
Gal(b1–3)GalNAc from either serine or threonine resi-
dues, but only after the terminal sialic acid has been
removed by neuraminidase. However, O-glycosidase
treatment alone also caused a more rapid migration (lane
4), suggesting that this effect is not due to the O-glycosi-
dase activity, but may instead be due to a contaminating
FIG. 5. Effect of pH on rHBsAg binding to apo H. Apo H (10 ng/ml) enzymatic activity. Treatment with both neuraminidase
was captured by MAb P2D4 precoated on microtiter wells. Wells were and O-glycosidase resulted in a migration slightly faster
incubated with rHBsAg (0.3 mg/ml) in 50 mM Na2HPO4 –citric acid buffer than neuraminidase treatment alone (lane 3). The addi-
(s); Tris–HCl buffer (l); Na2HPO4 –NaH2PO4 buffer (m) or glycine–
tion of O-glycosidase to apo H treated with neuramini-NaOH (,). Bound rHBsAg was detected with goat anti-HBs antiserum.
dase and N-glycosidase did not lead to further change
in its migration (lane 5 compared to lane 6), suggesting
that the contaminating enzymatic activity in the O-glycosi-We attempted to delipidate rHBsAg using the 1,1*,3,3*-
tetramethylurea protocol of Neurath and Strick (1994). In dase is another glycosidase activity that acts on N-gly-
cans, rather than O-glycans, but that it is not a protease.our hands, delipidation resulted in precipitation and loss
of 99% of the antigenicity of rHBsAg, as determined by The migration of apo H as a doublet is not altered by
any of these glycosidase treatments, suggesting that thea commercial assay (Abbott Auszyme), indicating dena-
turation of the rHBsAg proteins. Addition of a mixture two species in this purified preparation do not differ in
their carbohydrate structure.of phosphatidyl serine and phosphatidyl choline did not
restore antigenicity or solubility. In our assay, we were Each glycosidase-treated apo H preparation described
above was examined for its ability to bind rHBsAg, butunable to detect binding of delipidated or relipidated
rHBsAg using antibodies to rHBsAg. Neurath and Strick under nonreducing conditions required for this interac-
tion (Fig. 6B). None of the glycosidase treatments of apo(1994) had detected apo H instead. It is, nevertheless,
possible that the weak binding displayed by soluble or H altered its ability to bind to rHBsAg, indicating that the
carbohydrates on apo H are not necessary for rHBsAgmicrotiter-bound apo H is due to lipid binding. This bind-
ing activity is clearly different from the 100-fold greater binding. The migration rates of the reduced forms of apo
binding activity displayed by apo H after it attaches to
MAb P2D4.
Removal of carbohydrates from apo H. Previously, we
and others have cDNA-cloned and sequenced the apo
H gene, identifying four possible N-linked carbohydrate
attachment sites (Mehdi et al., 1991; Steinkasserer et al.,
1991). To examine the carbohydrates on apo H and to
determine whether they are required for rHBsAg binding,
purified apo H was treated with several glycosidases
and examined for altered electrophoretic migration and
for its ability to bind rHBsAg.
Apo H was digested with neuraminidase, O-glycosi-
dase, or N-glycosidase F, alone or in various combina-
tions, reduced, and displayed by electrophoresis (Fig.
6A). Without enzymatic digestion, purified apo H migrates
as a doublet. It migrates as a single species when exam- FIG. 6. Effects of glycosidase digestion of apo H on its ability to bind
ined directly from plasma, suggesting that one of the rHBsAg. After each glycosidase treatment, samples were dissolved in
reducing (A) or nonreducing (B) sample buffer, heated, separated bytreatments in purification modifies the protein or its asso-
SDS–PAGE, and electroblotted to nitrocellulose. Blots were probedciated carbohydrates (Mehdi et al., 1994). Neuraminidase
with rabbit antiserum to apo H (A), or with rHBsAg followed by MAbtreatment, which removes sialic acid, resulted in a 4-kDa
H166 against HBsAg (B). Treatments were as follows: no glycosidase
reduction in apparent molecular weight (lane 2) com- (lane 1); neuraminidase (lane 2); neuraminidase and O-glycosidase
pared to the untreated apo H (lane 1), indicating that apo (lane 3); O-glycosidase (lane 4); neuraminidase, O-glycosidase, and N-
glycosidase F (lane 5); N-glycosidase F (lane 6).H contains sialic acid. N-Glycosidase F, which cleaves
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FIG. 7. Effects of arginine and lysine modification of apo H on its ability to bind rHBsAg. (A) The arginines of purified apo H (1.5 mg/lane) were
modified by treatment with 1,2-cyclohexanedione: 0 (lane 1); 10 mM (lane 2); 40 mM (lane 3); or 100 mM (lane 4). (B) The lysines of purified apo H
(1 mg/lane) were acetoacetylated by treatment with diketene: 0 (lane 1); 0.064 mM (lane 2); 0.64 mM (lane 3); 6.4 mM (lane 4). (C) Acetoacetylation
was reversed by treatment with hydroxylamine. Purified apo H (0.75 mg/lane) was treated with diketene: 0 (lane 1); and 10 mM (lane 2). Following
the diketene treatment, the sample was desalted (lane 3) and further treated with 0.5 M hydroxylamine (lane 4). rHBsAg binding was assayed as
described in the legend to Fig. 6.
H (Fig. 6A) are slower than those of nonreduced apo H by diketene cannot be readily determined, the number
of modified lysines in a protein can be estimated by(Fig. 6B), probably due to the conformation maintained
by the disulfide bonds. But the apparent molecular weight amino acid analysis (Weisgraber et al., 1978). For this
purpose, aliquots of apo H were subjected to severalshifts caused by the glycosidase treatments are similar
regardless of the state of apo H oxidation. concentrations of diketene, and tested for their ability to
bind rHBsAg in a ligand blot. As shown in Table 1, treat-Modification of the basic amino acids in apo H. Apo
H is a relatively basic protein, containing 10 arginine and ment with 0.64 mM diketene resulted in the loss of 80%
of the rHBsAg binding activity. Amino acid analysis of29 lysine residues. To examine the possibility that these
basic amino acids are involved in rHBsAg binding, we this sample revealed that an average of 3 lysines of a
total of 29 in apo H were modified, indicating that a smalltreated apo H with reagents that modify arginines or
lysines. Chemical modifications of lysine and arginine number of lysine residues in apo H are critical for its
ability to bind rHBsAg. Apo H treated with 1000 timesresidues of another apolipoprotein, apo E, have pre-
viously been useful in identifying the role that these higher concentration of diketene (0.64 mM) had 15 of its
29 lysines modified, on average, and lost all of its bindingamino acids play in lipoprotein–receptor interactions
(Mahley et al., 1977; Weisgraber et al., 1978). activity (Table 1).
Two other lysine-modifying agents were similarlyTo modify arginine residues, apo H was treated with
1,2-cyclohexanedione. Under the mild conditions used, 1,2- tested. Potassium cyanate causes carbamylation of the
e-amino group of lysine, neutralizing its positive charge.cyclohexanedione reacts only with the guanido groups of
arginine (Mahley et al., 1977). Apo H treated with concentra- Reductive methylation with sodium borohydride and
formaldehyde also modifies lysine (Weisgraber et al.,tions of 1,2-cyclohexanedione as high as 0.1 M retained its
binding activity for rHBsAg as determined in the ligand 1978), but without altering its charge. Treatment of apo
H with either of these reagents resulted in the loss of itsblotting assay (Fig. 7A), indicating that the arginines in apo
H are not involved in this binding. ability to bind rHBsAg (X. Yang and M. E. Peeples, data
not shown). These results confirm that lysines in apo HTo modify lysine residues, apo H was treated with
diketene. Diketene causes an acetoacylation of the e- are important in its ability to bind rHBsAg and that the
charge of these lysines, as well as other aspects of theseamino group of lysine under the proper conditions (Weis-
graber et al., 1978), neutralizing the positive charge of residues, are important.
lysine. Apo H treated with diketene lost its rHBsAg bind-
ing activity in a dose-dependent manner (Fig. 7B), indicat-
TABLE 1ing that one or more lysines in apo H are important for
Effect of Acetoacetylation of Apo H Lysine ResiduesrHBsAg binding.
on Its Ability to Bind rHBsAgThe acetoacetylation caused by diketene can be re-
versed by treatment with hydroxylamine which removes
No. of modified
the acetoacetyl group, regenerating lysine (Weisgraber % binding lysine
et al., 1978). Again, diketene treatment resulted in the Diketene activity residuesa
loss of rHBsAg binding activity (Fig. 7C, lane 2). Hydroxyl-
0 100 0amine treatment restored the binding activity of diketene-
0.64 mM 20 3
treated apo H (lane 4), confirming that lysines are critical 0.64 mM 0 15
for this binding activity.
a From a total of 29 lysine residues.While the position(s) of the lysine(s) that are modified
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DISCUSSION on a MAb to bind rHBsAg maximally at neutral pH is
consistent with binding under physiological conditions.
Although the rHBsAg used in these studies containsOur initial attempts to identify a rHBsAg-binding pro-
a modified version of the large S protein in addition totein were made with hepatocyte plasma membrane and
the small S protein, rHBsAg containing only the small Sserum proteins treated with SDS, electrophoresed, and
protein is also able to bind to apo H, as is serum-derivedblotted to nitrocellulose. A protein, later identified as apo
HBsAg (Mehdi et al., 1994). Of course, in addition to smallH, was easily detectable as the only serum protein that
S protein, these rHBsAg particles also contain host cellbound rHBsAg (Mehdi et al., 1994). We also found that
lipids derived during the budding process. Neurath andapo H presented on a monoclonal antibody in a microtiter
Strick (1994) recently suggested that apo H might bindformat bound rHBsAg efficiently (Mehdi et al., 1994). In
to the lipids in HBsAg, rather than to the small S protein.this report, we demonstrate that rHBsAg binds to apo H
The binding activity they described was very weak, re-very poorly if the apo H is coated directly on the microtiter
minescent of the poor binding we found with soluble apowell, or presented as a soluble protein in a competition
H. They found that this weak binding was lost when theassay. Consistent with the poor binding ability of soluble
HBsAg was delipidated. We were unable to repeat theseapo H, we found that HBsAg isolated from serum does
experiments due to the loss of rHBsAg antigenicity andnot contain bound apo H. The approximately 100-fold
aggregation following the delipidation procedure. Weincrease in binding efficiency or competative efficiency
cannot, therefore, rule out the possibility that apo Hafter apo H associates with MAb P2D4 suggests that
weakly binds to the lipids in HBsAg.MAb binding may induce a change in apo H, resulting
We have also examined several structural parametersin a protein that is now highly reactive with rHBsAg. It is
of apo H. We had previously demonstrated that apo Hpossible that the SDS treatment of apo H in the initial
lost its ability to bind to rHBsAg after its disulfide bondsligand blotting procedure causes a similar change in apo
were disrupted (Mehdi et al., 1994). Here we found thatH, making it highly reactive with rHBsAg.
removal of sialic acid or all N-linked carbohydrates fromApo E, one of the two major apolipoproteins involved
apo H had no effect on rHBsAg binding, indicating thatin binding to apolipoprotein receptors, is unable to bind
rHBsAg binds to a protein rather than a carbohydrateto these receptors as a purified protein. When reconstitu-
moiety of apo H. Prior to these studies, we had usedted into lipid vesicles, apo E is again able to bind to its
small S protein-containing rHBsAg to survey a numberreceptor (Innerarity et al., 1979). Apo H might also alter
of cell lines for binding activity. While rHBsAg bound at
its reactivity when it associates with lipids. Interestingly,
a low level to many cell lines, it bound most efficiently
patients with primary anti-phospholipid syndrome and
to Vero and CV-1, African green monkey kidney-derived
a subset of patients with systemic lupus erythematosis
cell lines (Peeples et al., 1987). However, binding to Vero
produce antibodies described as ‘‘anti-phospholipid’’ or cells was enhanced by the presence of Ca2/, and sensi-
‘‘anti-cardiolipin’’ antibodies. However, these antibodies tive to neuraminidase treatment of the cells (Komai et
do not bind directly to the phospholipids; they bind in- al., 1988; Komai and Peeples, 1990). Both of these char-
stead to a complex of phospholipid and apo H (Galli et al., acteristics differ from the data presented here for apo H,
1990; McNeil et al., 1990). The anti-cardiolipin antibodies indicating that these are distinct binding activities.
may be binding to an epitope composed of modified Apo H is rich in basic amino acids which are relatively
cardiolipin or a combination of cardiolipin and apo H. easily modified by chemical treatment to test their impor-
Alternatively, cardiolipin binding may induce a conforma- tance in rHBsAg binding. Modification of arginine resi-
tional change in apo H, thereby revealing the anti-cardio- dues had no effect on binding, indicating that arginine
lipin antibody binding site. We are in the process of test- residues in apo H are not required for binding to rHBsAg.
ing whether apo H alters its conformation when it associ- Using the same arginine modification procedure, Weis-
ates with lipoproteins, becoming reactive with rHBsAg. graber et al. (1978) had found that arginine is important
The mechanism by which HBV enters hepatocytes to in the high-affinity binding of another apolipoprotein, apo
initiate infection is presently unknown. The findings that E, to its receptor.
human hepatoma cell lines are able to support full HBV In contrast, all modifications of lysine tested here de-
replication following transfection of the HBV genome stroyed the ability of apo H to bind rHBsAg. Acetoacetyla-
(Acs et al., 1987; Sells et al., 1987), but these same cells tion (diketene) and carbamylation (cyanate) result in neu-
are not susceptible to HBV infection, indicate that the tralization of the positive charge of the e-amino group,
receptor or another component needed for infection initi- which could directly prevent an ionic interaction between
ation is missing. We had previously demonstrated that a key lysine residue(s) and rHBsAg. Alternatively, binding
rHBsAg binds specifically to apo H (Mehdi et al., 1994), could be prevented through steric hindrance caused by
which, though not a hepatocyte plasma membrane pro- the bulk of the modifying group, or by alteration in the
tein, is associated with lipoproteins that are themselves conformation of the recognition site. Reductive methyla-
tion (sodium borohydride and formaldehyde), which doestargeted to the hepatocyte. The ability of apo H presented
AID VY 7696 / 6a0f$$$323 02-02-96 08:46:50 vira AP: Virology
65ALTERED APO H BINDS rHBsAg
not alter the charge of lysine, did abolish binding activity, other proteins with unknown functions have been shown
to bind HBsAg (Dash et al., 1992; Budkowska et al., 1993)indicating that charge is not the critical feature of lysine
needed for binding. Alterations in the conformation of the or to anti-idiotypic antibodies raised against the pre-S1
(Petit et al., 1992). Which, if any, of these proteins isbinding site, perhaps making the e-amino group unavail-
able for reactivity, are more likely to be responsible for involved in the initial stages of HBV infection has been
difficult to determine, primarily due to the lack of a sus-the loss of binding activity.
Acetoacylation (diketene) of apo H was particularly ceptible cell line that could be used to test specific
blocking reagents. A further complication is that someinformative. Not only did this modification result in loss
of binding activity, but also a level of diketene that de- of these proteins are found in or on cells that cannot be
infected, or are very poorly infected by HBV (Bchini etstroyed 80% of the binding activity corresponded to an
average modification of only three lysines per molecule. al., 1990).
This result suggests that three or fewer lysines are re-
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